| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 08/22/2002 | CA2434835A1 Novel modified released formulation |
| 08/22/2002 | CA2434833A1 Pharmaceutical composition for treating chronic heart failure |
| 08/22/2002 | CA2434641A1 Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability |
| 08/22/2002 | CA2434542A1 Novel modified release formulation |
| 08/22/2002 | CA2433936A1 Localized myocardial injection method for treating ischemic myocardium |
| 08/22/2002 | CA2433778A1 Thieno'2,3-d pyrimidindione derivatives as matrix metalloproteinase inhibitors |
| 08/22/2002 | CA2433075A1 Benzo thiadiazine matrix metalloproteinase inhibitors |
| 08/22/2002 | CA2432364A1 Bax-responsive genes for drug target identification in yeast and fungi |
| 08/22/2002 | CA2432111A1 Jfy1 protein induces rapid apoptosis |
| 08/22/2002 | CA2426535A1 Heteroaryl alkyl piperazine derivatives as fatty acid oxidation inhibitors |
| 08/22/2002 | CA2405532A1 Pyridoarylphenyl oxazolidinone antibacterials, and related compositions and methods |
| 08/22/2002 | CA2401383A1 Compositions of biochemical compounds involved in bioenergy metabolism of cells and method of use |
| 08/21/2002 | EP1233062A2 Destabilisation of viral quasi-species distributions - avoiding resistance phenomena |
| 08/21/2002 | EP1233018A2 Tricyclic biphenyl sulfonamide matrix metalloproteinase inhibitors |
| 08/21/2002 | EP1233017A1 Tricyclic sulfonamides useful as matrix metalloproteinase inhibitors |
| 08/21/2002 | EP1233016A1 Biphenyl sulfonamides useful as matrix metalloproteinase inhibitors |
| 08/21/2002 | EP1233015A1 Use of imidazole derivatives for the treatement of deseases involving the AT1 and AT2s receptors of angiotensine, some of these products, their preparation, their application as medicaments and pharmaceutical compositions containing them |
| 08/21/2002 | EP1232758A1 Polynucleotide formulated for improved intracellular transfer |
| 08/21/2002 | EP1232757A1 Remedies for diseases in association with decrease in bone mass |
| 08/21/2002 | EP1232756A1 Drugs, drinks or foods |
| 08/21/2002 | EP1232750A1 Non-beta-oxidizable fatty acid analogues and their use for reduction of growth of cancer cells |
| 08/21/2002 | EP1232749A1 Non-beta-oxidizable fatty acid analogues and their uses for inhibition of oxidative modification of low density lipoprotein |
| 08/21/2002 | EP1232748A1 Substituted nitrobenzene derivatives as medicines and other useful uses thereof |
| 08/21/2002 | EP1232747A2 Controlled release tablet of bupropion hydrochloride |
| 08/21/2002 | EP1232744A1 Composition containing vitamin C prepared during application |
| 08/21/2002 | EP1232743A1 Refreshing cosmetic and/or dermatological composition |
| 08/21/2002 | EP1232284A1 Genomic polymorphism for predicting therapeutic response |
| 08/21/2002 | EP1232266A2 Polypeptides and nucleic acids encoding same |
| 08/21/2002 | EP1232259A1 Human galanin family proteins and polynucleotides encoding the same |
| 08/21/2002 | EP1232247A2 Modulation of signal transduction |
| 08/21/2002 | EP1232187A1 Potentiation of inclusion complex formation of cyclodextrin derivatives |
| 08/21/2002 | EP1232179A1 15 human secreted proteins |
| 08/21/2002 | EP1232177A2 Methods and compositions for detection and treatment of breast cancer, based on breast cancer-associated polypeptides |
| 08/21/2002 | EP1232173A1 Fusidic acid derivatives |
| 08/21/2002 | EP1232172A1 Novel ribose compounds |
| 08/21/2002 | EP1232171A1 Method of preparing clarithromycin |
| 08/21/2002 | EP1232170A1 Antimitotic compounds |
| 08/21/2002 | EP1232169A1 Gallotannins and ellagitannins as regulators of cytokine release |
| 08/21/2002 | EP1232167A1 Synthetic oligomannosides, preparation and uses thereof |
| 08/21/2002 | EP1232165A1 Phosphorus-containing dendrimers as transfection agents |
| 08/21/2002 | EP1232160A1 Spiro(2h-1-benzopyran-2,4'-piperidine)derivates as glycine transport inhibitors |
| 08/21/2002 | EP1232158A1 Anti-inflammatory oxo derivatives and hydroxy derivatives of pyrrolizines, and their pharmaceutical use |
| 08/21/2002 | EP1232157A2 Non-aggregating, non-quenching oligomers comprising nucleotide analogues; methods of synthesis and use thereof |
| 08/21/2002 | EP1232156A1 Novel 1,2,3]-triazolo 4,5-d]pyrimidine compounds |
| 08/21/2002 | EP1232155A1 Protease inhibitors |
| 08/21/2002 | EP1232154A1 Protease inhibitors |
| 08/21/2002 | EP1232153A2 Imidazole derivatives and their use as raf kinase inhibitors |
| 08/21/2002 | EP1232150A1 Urea derivatives as anti-inflammatory agents |
| 08/21/2002 | EP1232148A1 Use of benzotriazole uv absorbers |
| 08/21/2002 | EP1232147A1 Triazoles as farnesyl transferase inhibitors |
| 08/21/2002 | EP1232146A1 4-(4'-hydroxyphenyl)amino-6,7-dimethoxyquinazoline to prevent development of colorectal cancer |
| 08/21/2002 | EP1232144A2 Novel il-8 receptor antagonists |
| 08/21/2002 | EP1232141A1 Ethers of o-desmethyl venlafaxine |
| 08/21/2002 | EP1232139A1 Nervonic acid derivatives, their preparation and use |
| 08/21/2002 | EP1231984A1 Phorboxazole derivatives for treating cancer |
| 08/21/2002 | EP1231983A2 Treatment of subnormal bone mineral density |
| 08/21/2002 | EP1231982A2 Use of phthalazine derivatives |
| 08/21/2002 | EP1231948A1 A propellant free spray-on skin patch composition for improving wound healing and for drug administration |
| 08/21/2002 | EP1231942A1 Cobalamin conjugates useful as imaging agents and as antitumor agents |
| 08/21/2002 | EP1231940A1 Stable amorphous amifostine composition, and preparation thereof |
| 08/21/2002 | EP1231939A2 Oncolytic combinations for the treatment of cancer |
| 08/21/2002 | EP1231938A2 Oncolytic combinations for the treatment of cancer |
| 08/21/2002 | EP1231926A2 New complex, and methods for its production and use |
| 08/21/2002 | EP1231925A1 Method and composition for the treatment of adenoviral ocular infections |
| 08/21/2002 | EP1231924A2 Treatment of systemic lupus erythematosus (sle) with dehydroepiandrosterone |
| 08/21/2002 | EP1231923A1 Protease inhibitors |
| 08/21/2002 | EP1231922A1 Protease inhibitors |
| 08/21/2002 | EP1231921A1 Protease inhibitors |
| 08/21/2002 | EP1231920A1 Solutions containing epinastine |
| 08/21/2002 | EP1231919A2 Novel class of cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof |
| 08/21/2002 | EP1231918A2 Novel composition based on a thiazolidinedione and metformin and use |
| 08/21/2002 | EP1231917A2 Pharmaceutical composition comprising a thiazolidinedione-metformin hydrochloride |
| 08/21/2002 | EP1231916A2 Use of indirubine derivatives for making medicines |
| 08/21/2002 | EP1231915A1 Use of pleuromutilin derivatives for transdermal treatment of bacterial diseases |
| 08/21/2002 | EP1231914A2 Nordihydroguaiaretic derivatives for use in treatment of tumors |
| 08/21/2002 | EP1231913A2 Treatment of cyclooxygenase-2 mediated disorders using conjugated fatty acid compounds |
| 08/21/2002 | EP1231912A1 Injectable preparation for controlling fish live comprising benzoyl urea derivatives |
| 08/21/2002 | EP1231911A1 Directly compressible, ultra fine acetaminophen compositions and process for producing same |
| 08/21/2002 | EP1231910A2 Inhibitors of endo-exonuclease activity such as pentamidine for treating cancer |
| 08/21/2002 | EP1231909A2 Use of ubiquinone q10 for the local treatment and prevention of post-surgical ophthalmologic pathologies |
| 08/21/2002 | EP1231908A2 Pharmaceutical composition comprising no or at least a no donor compound or another compound capable of releasing or inducing no formation in cells |
| 08/21/2002 | EP1231907A2 Dextrose and insulin fluid formulation for intravenous infusion |
| 08/21/2002 | EP1231904A2 A method of microencapsulation |
| 08/21/2002 | EP1231903A2 Coating of tablet cores |
| 08/21/2002 | EP1231900A1 Bilayered buccal tablets comprising nicotine |
| 08/21/2002 | EP1231899A2 Multilayer preparation for a controlled, pulsed release of active substances |
| 08/21/2002 | EP1231898A2 Apparatus and method for preparing microparticles |
| 08/21/2002 | EP1231894A1 Pharmaceutical formulations of salmeterol |
| 08/21/2002 | EP1231887A2 Method and composition for the treatment of scars |
| 08/21/2002 | EP1231877A1 Transdermal administration of huperzine |
| 08/21/2002 | EP1124550A4 Methods and compositions for selective cancer chemotherapy |
| 08/21/2002 | EP1105113A4 Composition and method for treating peyronie's disease and other sub-dermal plaque manifestation disorders |
| 08/21/2002 | EP1071330B1 Stabilization of isothiazolone |
| 08/21/2002 | EP1053224B1 Biphenylsulfonyl cyanamides, method for the production thereof and their utilization as a medicament |
| 08/21/2002 | EP1041991A4 Method for inhibiting cyclooxygenase-2 and tumor necrosis factor alpha |
| 08/21/2002 | EP1024800B1 Thyroxine analogues having no significant hormonal activity to treat malignant tumors |
| 08/21/2002 | EP0980251B1 Tissue factor for influencing blood vessel formation |
| 08/21/2002 | EP0956034B1 Pharmaceutical compositions for the treatment of transplant rejection, autoimmune or inflammatory conditions comprising cyclosporin a and 40-0-(2-hydroxyethyl)-rapamycin |
| 08/21/2002 | EP0900797B1 A 1-methylcarbapenem derivative |
| 08/21/2002 | EP0866654A4 Method for treating hepatitis virus infection |